Inga Rose

Inga Rose

Auto-generated profile, based on publicly available information

Inga Rose

Reference Medicine , 4050 E Cotton Center Blvd Bldg 3 Suite 38, 85040 Phoenix, AZ

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
ZGZoran Gatalica
Zoran Gatalica
NKNataliya Kuzmova
Nataliya Kuzmova
IRInga Rose
Inga Rose
MUMonika Ulamec
Monika Ulamec
MBMelita Perić Balja
Melita Perić Balja
Semir VranicSemir Vranic
Semir Vranic
In the current study, we assessed the prevalence and molecular features of HER2-low phenotype in the apocrine carcinomas of the breast (ApoCa) and its relationship with tumor-infiltrating lymphocytes (TILs). A cohort of 64 well-characterized therapy-naïve ApoCa was used. The TIL distribution was assessed using the hematoxylin and eosin whole slide/scanned images following the international TILs working group recommendations. Next-generation sequencing (NGS) was performed in a subset of HER2-low ApoCa. All patients were women, with a mean age of 62 years. Forty-three carcinomas were pure apocrine carcinoma (PAC; ER−/AR+), and the remaining 21 were classified as apocrine-like carcinomas (ALCs; ER+/−, AR+/−). HER2/neu was positive (score 3+ by IHC and/or amplified by FISH) in 20/43 (47%) PAC and 4/21 (19%) ALC. The prevalence of HER2-low expression (scores 1+ or 2+ without HER2 amplification) in ApoCa was 39% without significant differences between PAC and ALC (P = 0.14); however, the HER2-low phenotype was more prevalent in triple-negative PAC than in ALC (P < 0.001). Levels of TILs were low (≤10%) in 74% of ApoCa (median 5%, range 0%–50%). TIL levels were significantly higher in ALC than in PAC (P = 0.02). HER2 status had no impact on TIL distribution (P = 0.45). The genomic profile of HER2-low ApoCa was similar to other subtypes of ApoCa. ApoCa has predominantly low TIL, particularly PAC. The prevalence of the HER2-low phenotype in ApoCa is high, which should have therapeutic and clinical implications given the recently approved therapies with antibody–drug conjugates (ADCs) for HER2-low breast cancers.

7 July 2026 in Carcinogenesis
Verified
Journal Article
Open access
ZAZaineh Alnoubani
Zaineh Alnoubani
YKYoussuf Khanafer
Youssuf Khanafer
AFAdnan Fojnica
Adnan Fojnica
Emir BegagićEmir Begagić
Emir Begagić
IRInga Rose
Inga Rose
Semir VranicSemir Vranic
Semir Vranic
Androgen receptor splice variant 7 (AR-V7) is associated with resistance to androgen receptor-targeting therapies in prostate cancer, but its prevalence and clinical relevance in non-prostatic cancers remain incompletely characterized. A systematic review was conducted in accordance with PRISMA guidelines. Thirty-four studies, including 4855 clinical cases and 60 cell lines, were included. Overall, AR-V7 positivity was reported in 948/4855 clinical cases (19.5%); however, this represents a descriptive estimate across heterogeneous tumor types, study designs, and detection methods. Breast cancer accounted for 4057 of 4855 clinical cases (83.6%) and 815 of 948 AR-V7-positive cases (86.0%), with a within-cancer prevalence of 20.1%. However, after excluding the TCGA cohort in which AR-V7 was inferred through splice-junction analysis, the prevalence of AR-V7-positive breast cancer decreased to 9%. Higher tumor-specific proportions were observed in salivary duct carcinoma (55.2%), hepatocellular carcinoma (57.1%), and non-muscle-invasive bladder cancer (82.6%), but these estimates were based on smaller cohorts and should be interpreted cautiously. AR-V7 was present in several treatment-naive non-prostatic cancers, suggesting that it may represent a preexisting molecular feature in selected contexts. Current evidence suggests that AR-V7 warrants further investigation as a candidate biomarker. Standardized detection methods and prospective studies are needed before its clinical utility can be established.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
IRInga Rose
Inga Rose
HOHeather A. O'Neill
Heather A. O'Neill
ABAnnemarie Benton
Annemarie Benton
MRMelissa N. Richards
Melissa N. Richards
PEPhil Ellis
Phil Ellis
ZGZoran Gatalica
Zoran Gatalica
E23212 Background: IHC performance variability can occur due to multiple factors. Laboratories performing predictive IHC tests need to consider implementing additional QC procedures beyond those mandated by the regulatory agencies (QC of standard detection techniques). A thorough examination of the antibody (Ab) sensitivity, dynamic range, and specificity to the protein target of interest, as well as consistency of Ab production, should be examined when considering which antibody to implement in predictive clinical assays. Methods: Ab performance was analyzed using IHC, western blot (WB) and mass spectrometry (MS). IHC was performed on formalin fixed paraffin embedded (FFPE) tissues utilizing polymer detection systems and automated staining platforms (Ventana or DAKO). Abs were chosen based on published clinical predictive utility (PD-L1: Garon et al. NEJM 2015; TLE3: Kulkarni et al. Breast Cancer Res 2009; RRM1: Gong et al. Lung Cancer 2012). Primary Abs against PD-L1, TLE3 and RRM1 were probed by western blotting against cell lysates and recombinant protein. LC-MS/MS was used to examine the protein profile of bands that correlated with the positively staining bands observed in the WB. Results: Four anti-PD-L1 Abs (SP142, SP263, 22c3, and 28-8) showed consistent and expected reactivity to PD-L1 protein by WB with bands at 33kDa and 48-55kDa. By IHC there was > 90% concordance between 4 Abs in respect to cancer PD-L1 expression but a variable reactivity in the inflammatory cells. Three anti-TLE3 antibodies showed reactivity to the TLE3 protein in WB (83kDa), with additional, inconsistent binding at 55, 115 and 225kDa bands. Inconsistent staining by IHC was observed in FFPE tumor samples, resulting in elimination of 2 of the Ab candidates. Investigation of Ab performance consistency across 2 different lots of anti-RRM1 showed one lot reacting with a 90kDa band (expected RRM1), whereas the second lot did not detect a band at the expected MW. MS confirmed the target was only present in the bands of expected MW. Conclusions: The results demonstrate how WB and MS can be utilized as a supplement to traditional (tissue based) QC, in order to provide accuracy and precision needed in predictive biomarker testing.